Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*Andreas Wollenberg, Norito Katoh, Hidehisa Saeki et al.|British Journal of Dermatology|2020Cited by 590
Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meetingJochen Schmitt, Hywel C Williams, Phyllis I. Spuls et al.|Allergy|2012Cited by 189
Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trialLisa A. Beck, Amy S. Paller, Thomas Bieber et al.|Journal of the American Academy of Dermatology|2022Cited by 51
An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitisAyano Fukushima‐Nomura, Masayuki Amagai, Hiroshi Kawasaki et al.|Nature Communications|2025Cited by 18